Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 7,049 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 4
States / cities: Cullman, Alabama • Tampa, Florida • Boston, Massachusetts + 1 more

Conditions: Cocaine Dependence
Interventions: oxytocin, saline; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions: VGX-3100, Placebo, Electroporation (EP); Biological · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 22
States / cities: Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more

Conditions: Persistent Infection, Cystic Fibrosis
Interventions: CMTX-101, Placebo; Drug
Lead sponsor: Clarametyx Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 23
States / cities: Birmingham, Alabama • Palo Alto, California • San Franciso, California + 20 more

Conditions: Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions: Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo; Drug · Other
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 6 Years to 28 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Gastroparesis, Diabetes Mellitus
Interventions: Placebo, Relamorelin; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 113
States / cities: Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 95 more

Conditions: Type 2 Diabetes
Interventions: icovamenib 100 mg, Placebo; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Canoga Park, California • Long Beach, California + 17 more

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions: Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 204
States / cities: Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more

Conditions: Cornelia de Lange Syndrome
Interventions: N-acetyl cysteine, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 13 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cannabis Use Disorder
Interventions: Clonazepam, Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: lapatinib, placebo matching lapatinib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Detroit, Michigan • Lebanon, New Hampshire • Durham, North Carolina + 1 more

Conditions: Omega-3 Fatty Acids, Pediatric Bipolar Disorder, Adolescent Bipolar Disorder, Magnetic Resonance Spectroscopy Imaging
Interventions: Omega-3 Fatty Acid, Placebo; Dietary Supplement · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 12 Years to 18 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dietary Modification
Interventions: Tart cherry Juice, High-fat meal, Exercise; Dietary Supplement · Other
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Chronic Subdural Hematoma
Interventions: Memantine Hydrochloride, Placebo; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Liver Cirrhosis, Biliary
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 11
States / cities: Rialto, California • Sacramento, California • Miami, Florida + 8 more

Conditions: Healthy Volunteers, Propionic Acidemia, Methylmalonic Acidemia, Organic Acidemia
Interventions: BBP-671, Placebo; Drug
Lead sponsor: CoA Therapeutics, Inc., a BridgeBio company; Industry
Eligibility: 15 Years to 55 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Topeka, Indiana • Pittsburgh, Pennsylvania • Austin, Texas

Conditions: Moderate to Severe Atopic Hand and Foot Dermatitis
Interventions: dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 17
States / cities: Birmingham, Alabama • Redwood City, California • Washington D.C., District of Columbia + 14 more

Conditions: Alcohol Use Disorder
Interventions: ANS-6637 Low Dose, ANS-6637 High Dose, Matched Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes
Interventions: Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Chula Vista, California • Orlando, Florida

Conditions: Obesity
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 22
States / cities: Miramar, Florida • Orlando, Florida • Conyers, Georgia + 19 more

Conditions: Dyspepsia, Diabetes Mellitus With Gastrointestinal Symptoms
Interventions: Exendin 9-39, Microlipid, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: budesonide, placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 20
States / cities: Phoenix, Arizona • Orange, California • Palo Alto, California + 15 more

Conditions: Angioedema
Interventions: Placebo, Lanadelumab; Other · Drug
Lead sponsor: Takeda; Industry
Eligibility: 12 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 20
States / cities: Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 17 more

Conditions: Prostate Cancer
Interventions: Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 45
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more

Search by objective public record fields.

Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis

Effect of Oxytocin on Stress Response in Cocaine-dependent Individuals

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome

Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients

A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval

Omega 3 Fatty Acid Trial

Antioxidant Responses to Exercise and Cherry Consumption

Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD)

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

Development of a Selective ALDH2 Inhibitor to Treat AUD

Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus

Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation